Supplementary Material

A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas

Varun Monga, Umang Swami, Munir Tanas, Aaron Bossler, Sarah L. Mott, Brian J. Smith and Mohammed Milhem

**Figure S1.** Schematic representation of the treatment plan and different doses of drugs used. During maintenance phase patients received Bevacizumab at 15mg/kg Q 4 weeks and Valproic acid at 40mg/kg q 4 weeks for 5 days until tumor progression.